The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Mol Immunol. 2013 Nov;56(1-2):38-47. doi: 10.1016/j.molimm.2013.04.008. Epub 2013 May 14.
The continued global burden wrought by chronic infectious disease is unrelenting. Current therapies have curbed the severity of disease for patients, but Human Immunodeficiency Virus (HIV) and Hepatitis B (HBV) infection remain incurable and Mycobacterium tuberculosis (MTB) is rapidly becoming resistant to our existing antibiotics. Much attention has been given to enhancing T cell immunity through the use of certain common gamma-chain cytokines, which have proven to be essential and necessary for T cell survival and function. This article reviews the pre-clinical and clinical literature surrounding IL-2, IL-7, IL-15 and IL-21 and we comment on the potential therapeutic promise of these cytokines as adjuvant treatments for chronic infectious diseases.
慢性传染病给全球带来的持续负担是无情的。目前的治疗方法已经减轻了患者疾病的严重程度，但人类免疫缺陷病毒 (HIV) 和乙型肝炎病毒 (HBV) 感染仍然无法治愈，而结核分枝杆菌 (MTB) 对抗生素的耐药性正在迅速增加。人们一直关注通过使用某些常见的γ链细胞因子来增强 T 细胞免疫，事实证明，这些细胞因子对于 T 细胞的存活和功能是必不可少的。本文综述了围绕白细胞介素-2 (IL-2)、白细胞介素-7 (IL-7)、白细胞介素-15 (IL-15) 和白细胞介素-21 (IL-21) 的临床前和临床文献，并对这些细胞因子作为慢性传染病辅助治疗的潜在治疗前景进行了评论。
